Skip to search boxSkip to navigationSkip to main content

Cardiovascular Aging: From Molecular Mechanisms to Targeted Therapies

  • Jenyfer María Fuentes-Mendoza
    ,
  • Marcio José Concepción-Zavaleta(corresponding author)
    ,
  • Juan Muñoz-Moreno
    ,
  • Luis Concepción-Urteaga
    ,
  • José Paz Ibarra
    ,
  • Regina Garza-Boullosa
*Corresponding author for this work
  • Universidad Científica del Sur
    ,
  • ,
  • Eastern Virginia Medical School
    ,
  • Universidad Nacional de Trujillo
    ,
  • Hospital Nacional Edgardo Rebagliati Martins, EsSalud
    ,
  • Universidad Nacional Mayor de San Marcos
Research Output:
Contribution to journal
Review article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 759-772 (14 pages)

Journal (Volume, Issue Number)

Molecular Diagnosis and Therapy (Volume 29, Issue 6)

Publication milestones

  • Published - 11/2025

Publication status

Published - 11/2025

ISSN

1177-1062

Publication IDs

  • Scopus: 105014214726
  • PubMed: 40856932

Abstract

Cardiovascular aging is a complex biological process involving progressive cellular and molecular changes that impair heart and vascular function. This review evaluates both fundamental mechanisms and therapeutic strategies, focusing on how recent advances in pharmacology, gene therapy, and regenerative medicine can be translated into clinical practice to mitigate age-related cardiovascular decline. We conducted a comprehensive analysis of peer-reviewed studies from 2000 to 2023, examining molecular pathways of cardiovascular aging and their modulation through pharmacological, genetic, and lifestyle interventions. The review prioritized clinical trials, translational research, and meta-analyses to assess therapeutic efficacy and safety. Current evidence highlights the effectiveness of senolytic drugs such as dasatinib and quercetin in reducing age-related cardiovascular dysfunction, while rapamycin and metformin show promise in improving cardiac longevity through metabolic regulation. Gene therapies, including clustered regularly interspaced short palindromic repeats (CRISPR)-based interventions, demonstrate potential in preclinical models for cardiac regeneration. Stem cell therapies and nanotechnology-based drug delivery systems are emerging as innovative approaches to enhance tissue repair. In addition, lifestyle modifications such as Mediterranean diet adherence and exercise significantly improve vascular health in aging populations. However, challenges remain in drug delivery, patient-specific responses, and long-term safety of novel therapies. The integration of targeted pharmacological treatments, advanced regenerative techniques, and personalized lifestyle interventions represents a transformative approach to managing cardiovascular aging. Future research should focus on optimizing therapeutic combinations, refining delivery methods, and validating biomarkers for clinical monitoring. A multidisciplinary strategy combining these advances will be essential to improve cardiovascular outcomes in aging populations.